HAYA Therapeutics

HAYA Therapeutics is a precision therapeutics company focused on the discovery and development of innovative tissue- and cell-selective genomic medicines for the treatment of fibrotic diseases and other serious health conditions associated with aging, including cancer. The company’s discovery engine focuses on long non-coding RNAs (lncRNAs) in the “dark matter” of the human genome — key tissue- and cell-specific drivers of fibrosis and other disease processes — to identify novel targets and drug candidates with the potential for greater efficacy and safety compared to existing therapies. HAYA’s lead therapeutic candidate is an antisense molecule targeting Wisper, a major driver of cardiac fibrosis enhancement, which has demonstrated the ability to halt and potentially reverse the fibrotic process of heart failure in preclinical testing. The company is also developing an lncRNA-targeted candidate for tissue-specific treatment of fibrotic diseases in other tissues, including the lung, kidney, liver, and the microenvironment of solid tumors. HAYA, headquartered at Biopôle SA, the life sciences park in Lausanne, Switzerland, is led by a world-class team of experts in lncRNA biology and fibrotic diseases and is supported by a strong consortium of investors.